Global Health Breakthrough: Semaglutide Production Costs Could Plunge to US$3 Monthly as Patents Expire

Researchers estimate semaglutide (Ozempic/Wegovy) could be produced for US$3/month as patents expire, offering a major health boost for developing nations.

By: AXL Media

Published: Mar 6, 2026, 7:08 AM EST

Source: The information in this article was sourced from CNA

The Economic Shift of Blockbuster Weight-Loss Molecules

The financial landscape for one of the world’s most sought-after medical treatments is on the verge of a radical transformation. Researchers announced on Friday that semaglutide, the primary molecule driving Novo Nordisk’s wildly successful Ozempic and Wegovy brands, could soon be manufactured for as little as US$3 for a 30-day supply. This estimate, based on the manufacturing trajectories of other off-patent medicines, contrasts sharply with the current US retail price, which frequently exceeds US$200 per month for the branded versions.

Implications of Imminent Patent Expirations

The window for generic manufacturing is set to open significantly as semaglutide loses its patent protection in major markets, including Brazil, China, and India, later this month. Furthermore, the study identified approximately 150 countries where the drug was never patented to begin with. These 160 nations represent a critical demographic, accounting for 69 percent of the global population living with Type 2 diabetes and 84 percent of those suffering from clinical obesity. The researchers argue that this convergence of legal and economic factors creates a unique "medical success story" opportunity.

Addressing the Global Burden of Chronic Disease

Obesity and diabetes are no longer merely lifestyle concerns but are recognized as chronic drivers of stroke, heart disease, kidney failure, and various cancers. Currently, clinical obesity contributes to an estimated 3.7 million deaths annually, while Type 2 diabetes remains a leading cause of blindness and limb amputations worldwide. Dr. Samuel Cross of Imperial College London noted that reducing prices to sustainable levels is not just a matter of market competition, but a necessary public health intervention to save millions of lives in underserved regions.